BOSTON — Callodine Group has appointed veteran investor Winston Black to head its newly established Life Sciences Finance Strategy, as the firm expands its footprint in structured credit within the healthcare sector. Black will lead investment sourcing, underwriting, and portfolio management efforts focused on commercial-stage life sciences companies.
The move signals Callodine’s strategic push into specialized private credit, particularly within the innovation-driven life sciences market.
“Winston’s experience, industry knowledge, and deep credit background make him a tremendous addition to the Callodine platform,” said James Morrow, CEO of Callodine. “We believe the current market presents a compelling opportunity in life sciences finance.”
Black brings over 25 years of investment and operational experience, with a track record of deploying more than $1 billion across structured credit and asset-based deals in the healthcare sector. Most recently, he served as CEO and Chairman of SWK Holdings (NASDAQ: SWKH), where he led the firm’s life sciences finance strategy from 2012 to 2022. He previously co-founded PBS Capital Management and held senior roles at Highland Capital Management, overseeing a $2.3 billion healthcare portfolio.
“Driven by innovation, the life sciences market offers compelling investment opportunities aimed at improving patient outcomes and lowering healthcare costs,” Black said. “I’m excited to join Callodine and help drive its commitment to value creation through specialized investment strategies.”
The appointment underscores Callodine’s broader initiative to expand its private credit capabilities across income-generating asset classes within the middle market.
